Request to Join
has invited you to join this group
Marc S. Sabatine, MD, MPH is Chairman of the Thrombolysis in Myocardial Infarction (TIMI) Study Group, the Lewis Dexter, MD, Distinguished Chair in Cardiovascular Medicine at Brigham and Women’s Hospital (BWH), and a Professor of Medicine at Harvard Medical School (HMS). Dr. Sabatine graduated magna cum laude from Harvard College and received his medical degree magna cum laude from HMS. He did his Internal Medicine residency, Chief Residency, and Cardiology clinical fellowship at the Massachusetts General Hospital (MGH). He received a Master of Public Health degree from the Harvard School of Public Health. Dr. Sabatine is board certified in Internal Medicine and Cardiology and attends in the coronary care units at both BWH & MGH. He is a Fellow of the American Heart Association, the American College of Cardiology, and the European Society of Cardiology. As Chairman of the TIMI Study Group, Dr. Sabatine leads an Academic Research Organization whose mission over the past 30+ years has been to advance the knowledge and care of patients suffering from cardiovascular disease and its risk factors. To that end, Dr. Sabatine has led several large-scale, international, randomized controlled trials of novel antithrombotic, lipid-lowering, and other pharmacotherapies. A pioneer in the multimarker approach to risk stratification, Dr. Sabatine has several NIH grants supporting the application of proteomics and metabolomics for discovery of novel biomarkers. He has a long-standing interest in pharmacogenetics and has made seminal observations on the ability to use genetics for personalized medicine. Dr. Sabatine has authored over 200 original research, peer-reviewed articles including in the New England Journal of Medicine, JAMA, and the Lancet. Dr. Sabatine has given Cardiology or Medical Grand Rounds at top academic centers around the world and has authored numerous review articles and book chapters. He is the recipient of multiple honors and awards including the ACC Zipes Distinguished Young Scientist Award and has been inducted into the American Society of Clinical Investigation. He is on the writing committees for several ACC/AHA practice guidelines. He is a Deputy Editor for JAMA Cardiology.
Peter Sever is Professor of Clinical Pharmacology and Therapeutics at Imperial College London and Honorary Consultant Physician at the Imperial College Healthcare NHS Trust. He is co-Director of the International Centre for Circulatory Health and Head of the Physiology and Prevention Section of the National Heart and Lung Institute, Imperial College London. In 2009, was appointed as a Senior Investigator of the National Institute for Health Research and reappointed in 2014. After graduating from the University of Cambridge, Professor Sever completed his training at St Mary’s Hospital Medical School in London. He became an Honorary Consultant Physician and Senior Lecturer in Medicine at St Mary’s Hospital in 1976. In 1980, he was appointed Professor of Clinical Pharmacology and Therapeutics at St Mary’s Hospital Medical School, which was subsequently incorporated into the Imperial College School of Medicine. Professor Sever is Joint Editor-in- Chief of the Journal of the Renin-Angiotensin- Aldosterone System. Professor Sever is a past President of the British Hypertension Society and the European Council for Blood Pressure and Cardiovascular Research and past Chairman of the Fellowships Committee of the British Heart Foundation. He is also a Fellow of the European Society of Cardiology. In 2010, he was presented with the Astra-Zeneca Award from the International Society for Hypertension for his contribution to the clinical pharmacology and therapy of arterial hypertension. He was elected an Honorary Fellow of Trinity Hall Cambridge in 2011. Professor Sever’s research interests include the pathophysiology of vascular disease, the evaluation of antihypertensive drug therapy and the impact of multiple risk factor intervention for the prevention of cardiovascular disease.
Terje R. Pedersen, MD is professor emeritus (Preventive Cardiology) at the University of Oslo, Norway and retired Head of Research at the Centre for Preventive Medicine at Oslo University Hospital, Ullevål. His main interest is in preventive cardiology and he has been the principal investigator in several major clinical trials like The Norwegian Timolol Trial, the Scandinavian Simvastatin Survival Study (4S) , the IDEAL study and the SEAS study. He is Co-chair of the Executve Committee of the FOURIER trial, with 27 564 patients to study the effect of evolocumab, a PCSK9 inhibitor, on the prognosis in patients with CVD.